VERNEREY Déwi
3 le coteau
25115 POUILLEY-LES-VIGNES
dvernerey@chu-besancon.fr
French citizenship
Driving license



Research Engineer in Epidemiology & Biostatistics

(Ph.D. / + 23 years' experience)

➢ WORK EXPERIENCE

Since 2013 **Research Engineer in Epidemiology & Biostatistics (permanent contract CHRU: "Ingénieur Principal")** in the Methodology and quality of life in Oncology Unit (UMQVC) **at the University hospital of Besancon**.

Since 2021 Head office of the UMQVC

Teacher (vacation university). in statistics, data analysis and methodology in master's degree and in medical school.

Expert / consultancy in Methodology, Epidemiology and Biostatistics

2010 – 2013 **Research Engineer in Epidemiology & Biostatistics (permanent contract INSERM)** at PARCC (Paris Cardiovascular Research Center) located in Georges Pompidou European hospital.

2008 – 2010 **Biostatistician (permanent contract)** at «***Genetic diseases Institute*** **»** in Necker Hospital.

2006 – 2008 **Research Engineer in Statistics (fixed-term contract)** at **INSERM U535 Unit** (Epidemiologic Genetics and Human Populations Structure - Paul Brousse Hospital - Villejuif).

2005 **Biostatistician (fixed-term contract)** at **Sanofi Aventis R&D Center** (Chilly Mazarin)

2005 **Teacher at Public Health and Epidemiology Summer School** *« Ecole d'été de santé publique et d'épidémiologie »* at Paris XI University (Kremlin Bicêtre Hospital)

2004 – 2005 **Biostatistician (fixed-term contract)** in « **Institut Gustave Roussy » (IGR-**Villejuif) Biostatistics and Epidemiology department.

➢ EDUCATION

2013 – 2016 **PhD in epidemiology and statistics**
Burgundy and Franche-Comté University.

2002 – 2003 **Master's degree in Mathematical Engineering -** major: Engineering Statistics – graduated cum laude
Joseph Fourier University, Grenoble 38.

1999 – 2002 **Bachelor and Master's degree in Mathematics** - graduated cum laude

Two-Year University degree in Mathematics and Informatics Applied to Science-graduated cum laude
« UFR Sciences et Techniques » of Franche-Comté, Besançon, 25.

1999 **BACCALAUREAT in Science (major mathematic)** followed by a one-year preparatory classes for entrance to "Grandes Ecoles" in the field of science
Victor Hugo High School, Besançon 25.

➢ ADVISORY BOARD

Since 2017 Member of the HaliodDx's Digestive Scientific Advisory Board (2017-2019)

Since 2017 Member of the ARCAD Foundation's Scientific Advisory Board (2017-XXXX)

Since 2018 Member of the Canceropôle Grand Est Scientific Advisory Board (2018-XXXX)

Since 2023 Member of the GERCOR Scientific Advisory Board (2023-XXXX)

Since 2023 Member of the PRODIGE Scientific Advisory Board (2023-XXXX)

Since 2024 Member of the Registre des Tumeurs du Doubs Scientific Advisory Board (2024-XXXX)

➢ INTERNATIONAL AND NATIONAL RESPONSABILITIES

Since 2017 Member of the ARCAD group

Since 2017 Head of GERCOR statistical team (INCA's labeled data center)

Since 2020 Member of the GERCOR group

Since 2020 Member of the PRODIGE Intergroup

➢ LOCAL RESPONSABILITIES

Member of the liaison committee, coordination committee, quality committee, single point of access for health data and scientific council within the research governance framework at the Besançon University Hospital (CHU de Besançon)

➢ SUPERVISING

Since 2016 Supervision of students in Master degree in statistics and in medical thesis

Since 2017 Supervision of 2 PhD students in statistics

➢ FIELD OF EXPERTISE

Epidemiology, Biostatistics, Clinical trials design and Analysis

Clinical Research

Oncology, Kidney and Heart Transplantation, Cardiovascular diseases, Monogenic genetic diseases (rare) & multifactorial (frequent), Pathology, Immunology, transfusion

➢ PUBLICATION PRODUCTION INDICATORS

Publications indexed in Pubmed : 189
h-index : Overall : 49 / Since 2021: 42
I10 index : Overall : 142 / Since 2021 : 130
Citations: Overall : 14265 / Since 2021 8653

Since 2013:

Publications indexed in Pubmed: 174 (A+: 6; A: 60; B: 52; A+/A/B: 70%)
SIGAPS Score: 2023
Score Frac: 83.79

➢ MAJOR 30 PUBLICATIONS

1. Samaille T, Henriques J, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Garcia-Larnicol ML, Cohen R, **Vernerey D**, Lefevre JH, Svrcek M, André T
Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinical Trial
JAMA Oncology (2026)

2. Thibault C, Bennamoun M, Fléchon A, Gravis G, Pouessel D, Combe P, Borchiellini D, Loriot Y, Laguerre B, Barthélémy P, Huillard O, Gross-Goupil M, Le Roy A, Jaffrelot L, Cancel M, Audenet F, Belhouari H, Kaci G, Lepicard E, **Vernerey D**, Henriques J, Oudard S.
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study
Journal of Clinical Oncology. (2026)

3. Alves Costa Silva C, Machaalani M, Saliby RM, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, **Vernerey D**, Lee GM, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Choueiri TK, Albiges L.
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.
Nature Medicine (2026)

4. E Brain, O Mir, E Bourbouloux, O Rigal, JM Ferrero, S Kirscher, D Allouache, V D'Hondt, AM Savoye, X Durando, FP. Duhoux, L Venat-Bouvet, E Blot, JL Canon, F Rollot, H Bonnefoi, T Roque, A Latouche, J Henriques, M Lacroix-Triki, **D Vernerey**
Adjuvant chemotherapy versus none in women aged 70 years and older receiving adjuvant hormonotherapy for high-risk breast cancer according to genomic grade index: the Unicancer ASTER 70s randomized phase III trial
The Lancet (2025)

5. Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, Hammel P, Regenet N, Taieb J, Turrini O, Paye F, Turpin A, Souche FR, Laurent C, Kianmanesh R, Michel P, **Vernerey D**, Mabrut JY, Turco C, Truant S, Sa Cunha A; PANACHE01-FRENCH08-PRODIGE48 Investigators; TransSCOT Consortium.
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).
Journal of Clinical Oncology (2025)

6. Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, Bennouna J, Artru P, Louvet C, Lepere C, Emile JF, Bouche O, Mazard T, **Vernerey D**, Vogiatzoglou K, Tzardi M, Sharma S, Liu MC, Sethi H, André T, Galon J, Laurent-Puig P.
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.
Journal of Clinical Oncology (2025)

7. Gallois C, Sroussi M, André T, Mouillet-Richard S, Agueeff N, Mulot C, **Vernerey D**, Louvet C, Bachet JB, Dourthe LM, Mazard T, Jary M, Coutzac C, Lecaille C, Tabernero J, Van Laethem JL, Lepage C, Emile JF, de Reyniès A, Taieb J, Laurent-Puig P.
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.
Journal of Clinical Oncology (2025)

8. Thariat J, Bosset M, Falcoz A, **Vernerey D**, Pointreau Y, Racadot S, Faivre JC, Castelli J, Guihard S, Huguet F, Chapet S, Tao Y, Borel C, Fayette J, Rambeau A, Ferrand FR, Pechery A, Bourhis J, Sun XS;
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.
International Journal of Radiation Oncology, Biology, Physics (2025)

9. Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L,

Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, **Vernerey D**, Taïeb J, Borg C
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncology (2024)

10. Adotevi O, **Vernerey D**, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Journal of Clinical Oncology (2023)

11. André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, **Vernerey D**, Henriques J, Lefevre JH, Svrcek M.
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
Journal of Clinical Oncology (2023)

12. Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, **Vernerey D**, Taieb J, Svrcek M; for PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER.
Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Annals of Oncology (2023)

13. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, **Vernerey D**, Oki E, Georgoulias V, Ben-Aharon I, Shi Q
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
Journal of Clinical Oncology (2021)

14. Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, **Vernerey D**, André T, Laurent-Puig P.
Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial.
Clinical Cancer Research (2021)

15. André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, **Vernerey D**, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q.
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
Lancet Oncolology (2020)

16. Cohen R, **Vernerey D**, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group.
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
European Journal of Cancer (2020)

17. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J, Souglakos L, Shi Q, Kerr R, Labianca R, Meyerhardt J, **Vernerey D**, Yamanaka T, Boukovinas L,. Meyers J, Renfro L, Niedzwiecki D, Torri V, Sargent D, Andre T, Iveson T
Duration (3 versus 6 months) of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer
New England Journal of Medicine (2018)

18. Auclin E, André T, Taieb J, Banzi M, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, **Vernerey D**
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
British Journal of Cancer (2019)

19. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J, Souglakos L, Shi Q, Kerr R, Labianca R, Meyerhardt J, **Vernerey D**, Yamanaka T, Boukovinas L,. Meyers J, Renfro L, Niedzwiecki D, Torri V, Sargent D, Andre T, Iveson T
Duration (3 versus 6 months) of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for stage III colon cancer
New England Journal of Medicine (2018)

20. Thierry A, **Vernerey D**, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France phase III trial
Journal of Clinical Oncology (2018)

21. Auclin E, Zaanan A, **Vernerey D**, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
Annals of Oncology (2017)

22. Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d' Engremont C, Dupont-Gossart A-C, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, **Vernerey D**
Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma
Journal of the National Cancer Institute (2017)

23. **J**ary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
International Journal of Cancer (2016)

24. André T, de Gramont A, **Vernerey D**, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
Journal of Clinical Oncology. (2015)

25. Tournigand C, Chibaudel B, Samson B, Scheithauer W, **Vernerey D**, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
The Lancet Oncology. (2015)

26. Aubert O*, Kamar N*, **Vernerey D***, Viglietti D, Martinez F, Duong-Van-Huyen J-P, Eladari D, Empana J-P, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A
Long-term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.
British Medical Journal. **(2015)**
*Co first authorship

27. Loupy A*, **Vernerey D***, Tinel C, Aubert O, Duong van Huyen J-P, Rabant M, Verine J, Nochy D, Empana J-P, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
Journal of the American Society of Nephrology (2015)
*Co first authorship

28. Loupy A, Lefaucheur C, **Vernerey D**, Prugger C, Duong van Huyen J-P, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana J-P, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X *Complement-binding anti-HLA antibodies and kidney-allograft survival.*
New England Journal of Medicine (2013)

29. Lefaucheur C, Loupy A, **Vernerey D**, Duong-Van-Huyen J-P, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana J-P, Hill GS, Glotz D, Legendre C, Jouven X
Antibody-mediated vascular rejection of kidney allografts: a population-based study.
The Lancet (2013)

30. Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, Périer M-C, Marijon E, **Vernerey D**, Empana J-P, Jouven X
Main air pollutants and myocardial infarction: a systematic review and meta-analysis.
JAMA (2012)

➢ MAJOR COMMUNICATIONS

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

- Oral Communication at : the Annual meeting of the French Pancreatic Club in 2014, Paris, France; the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain. the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in 2015, San Francisco, United States of America; the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in 2014, Barcelona, Spain.
- Poster discussion at the American Society of Clinical Oncology Annual meeting in 2014, Chicago, United States of America.
- Selection for poster of distinction at the American Pancreatic Association in 2015, San Diego, United States of America.

E. Auclin, T. Andre, J. Taieb, M. Banzi, J.-L. van Laethem, J. Tabernero, T. Hickish, A. De Gramont, **D. Vernerey**
Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial

- Poster discussion at the European Society for Medical Oncology Annual meeting in 2018, Munich, Germany.

➢ AWARDS

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

- Best Abstract in Clinical Science at the Annual meeting of the French Pancreatic Club in 2014, Paris, France
- Best Abstract in Clinical Science at the Annual meeting of the European Pancreatic Club in 2015, Toledo, Spain.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

- Best Abstract in Colorectal Cancer at the JFHOD annual congress in 2016, Paris, France

C. Neuzillet, A. Casadei Gardini, B. Brieau, C. Vivaldi, C. Smolenschi, G. Brandi, D. Tougeron, R. Filippi, A. Vienot, N. Silvestris, A.-L. Pointet, S. Murgioni, B. Rousseau, M. Scartozzi, L. Dahan, T. Boussaha, S. Crusz, A. Meurisse, A. Lievre, **D. Vernerey**
Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations

- Best Poster at the European Society for Medical Oncology Annual meeting in 2018, Munich, Germany.

➢ LISTE EXHAUSTIVE DES PUBLICATIONS

PMID	Titre de la publication	Liste des auteurs	Revue	Publication année
42879140	Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinical Trial.	Samaille T, Henriques J, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Garcia-Larnicol ML, Cohen R, **Vernerey D**, Lefevre JH, Svrcek M, André T.	JAMA Oncol	2026
42772370	Impact of CT scan-based vs. minimal follow-up on patient-reported outcomes after surgery for non-small cell lung cancer in IFCT-0302 phase III trial.	Eberst G, Henriques J, Thomas PA, Giroux-Leprieur E, Mercier O, Pagès PB, Ravier P, Bayle S, Valette CA, Berard H, Lagrange A, Bonnefoy P, Langlais A, **Vernerey D**, Anota A, Morin F, Westeel V	J Thorac Cardiovasc Surg	2026
42520930	Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).	Noé C, Henriques J, Chanez B, **Vernerey D**, Lecomte T, Durand A, Assenat E, Edeline J, Heurgué A, Tougeron D, Manfredi S, Hautefeuille V, Neuzillet C, Roth G, Lagasse JP, Tournigand C, Delaye M, Hollebecque A, Turpin A, Parent P.	JHEP Rep	2026
42404549	Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial.	A El Kaddissi, A Vienot, J-D Fumet, A Meurisse, T Nguyen, E Klajer, A Bouard , L Spehner, F Fein , M Stouvenot, E Dochy, M Rebucci-Peixoto, H Almotlak, J Henriquez, Z Selmani, **D Vernerey**, E Hervouet, A Folletet, S Kim, F Ghiringhelli, C Borg	ESMO Gastrointest Oncol	2025
42396273	Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.	Rousseau B, Hilmi M, Falcoz A, **Vernerey D**, Toullec C, Lecomte T, Lambert A, Tournigand C, Guerin-Meyer V, Louvet C, Trouilloud I, Rinaldi Y, Coriat R, Dauba J, Neuzillet C, André T, Bachet JB, Cros J, de la Fouchardiere C, Garcia-Larnicol ML, de Gramont A, Hammel P.	medRxiv	2026
42379715	Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.	Meskauskas A, Cohen R, **Vernerey D**, Bachet JB, Lacroix L, Laurent-Puig P, Paye F, Di Fiore F, Boige V, Garcia-Larnicol ML, Evrard C, Goumard C, Gelli M.	BMJ Open	2026
42285832	Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors.	Jehanno L, Henriques J, Samaille T, Loisel C, Cervantes B, Colle R, **Vernerey D**, André T, Cohen R.	Clin Colorectal Cancer	2026
42190158	Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.	Thibault C, Bennamoun M, Fléchon A, Gravis G, Pouessel D, Combe P, Borchiellini D, Loriot Y, Laguerre B, Barthélémy P, Huillard O, Gross-Goupil M, Le Roy A, Jaffrelot L, Cancel M, Audenet F, Belhouari H, Kaci G, Lepicard E, **Vernerey D**, Henriques J, Oudard S.	J Clin Oncol	2026
41985224	Surgical modality non-inferiority testing with an intensification of adjuvant treatments: a missed opportunity.	Lecuru, FR ; Cibula, D ; **Vernerey, D**	Int J Gynecol Cancer	2026
41980356	Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO.	Boisteau E, Boilève A, Tougeron D, **Vernerey D**, De Malet A, Lecomte T, Aparicio T, Pernot S, Pinot J, Pellat A, Hautefeuille V, Farès N, Desgrippes R, Coriat R, Zaanan A, Edeline J, Philonenko S, Dubreuil O, Henriques J, Turpin A.	Eur J Cancer	2026
41886725	Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.	Marques A, Henriques J, **Vernerey D**, Parc Y, Lefevre JH, Voron T, Cohen R, André T, Samaille T.	JCO Oncol Pract	2026

41749511	Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer.	Lecoester B, Xie Y, Sun X, Renaudin A, Ndao B, Boullerot L, Malfroy M, Arnier R, Boisson C, Laheurte C, Meurisse A, Chevalier C, Vulquin N, Thibouw D, Benhmida S, Pernot M, **Vernerey D**, Mirjolet C, Guo J, Boustani J, Adotevi O.	Oncoimmunology	2026
41729638	[Breast cancer: an example of changing practices that take age-related factors into account. About the ASTER 70s study].	Brain É, Rollot-Trad F, Rochette de Lempdes G, Bringuier M, Roque T, Henriques J, **Vernerey D**.	Rev Prat	2026
41605424	Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.	Foret T, Dufrost V, Lagrange J, Regnault V, Lakomy C, Mourey G, Lecompte T, Zuily S, **Vernerey D**, Henriques J, Magy-Bertrand N, Wahl D.	Thromb Haemost	2026
41547566	Interpreting the pT1 subgroup in the ASTER 70s trial - Authors'' reply.	Brain, E ; Rollot-Trad, F ; Roques, T ; Henriques, J ; **Vernerey, D**	Lancet	2026
41501493	Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.	Alves Costa Silva C, Machaalani M, Saliby RM, Zhong C, Xie W, Pasolli E, Piccinno G, Dalban C, Fidelle M, Meurisse A, **Vernerey D**, Lee GM, Birebent R, Saad E, Steiner C, Flippot R, Barros-Monteiro J, Segata N, Thiery-Vuillemin A, Formenti S, Kuznetsova T, Escudier B, Derosa L, Zitvogel L, Choueiri TK, Albiges L.	Nat Med	2026
41444692	Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.	Dutheil J, Pereira V, Boisson C, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Viot J, Meynard G, Goujon M, Dalens L, Dubourd C, Marchi S, Meneveau N, **Vernerey D**, Adotévi O, Meurisse A, Curtit E.	Breast Cancer Res	2025
41352456	Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.	Maury, P ; Sayous, Y ; **Vernerey, D** ; Sun, XS ; Bourhis, J ; Falcoz, A & al	Radiother Oncol	2026
41276451	Neoadjuvant pembrolizumab with a watch-and-wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 - PRODIGE 84 phase II trial (PREMICES).	Lefevre JH, Dubreuil O, Colle R, Tougeron D, Vienot A, Dupré A, Toullec C, Smith D, Guimbaud R, Chibaudel B, Garcia Larnicol ML, **Vernerey D**, Cohen R	Dig Liver Dis	2026
41202834	Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.	Kim S, Boustani J, Iseas S, **Vernerey D**, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouché O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C;	Lancet Oncol	2025
40833930	Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study	Zaanan A, Bergen ES, Evesque L, Meurisse A, Artru P, Lecomte T, Bouché O, Lepère C, Ambrosini M, Coriat R, Lièvre A, Cohen R, Boige V, Louafi S, Bachet JB, Goyer S, Taieb J, **Vernerey D**, Blons H, Laurent-Puig P.	J Natl Cancer Inst	2025
40752909	Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial	Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, **Vernerey D**.	Lancet	2025
40714135	Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the A GORTEC 2014-	Maury P, Sayous Y, Marnaoui R, Loiseau C, Khalladi N, Sun XS, Bourhis J, **Vernerey D**, Falcoz A, Thariat J.	Int J Radiat Oncol Biol Phys	2025

	04 "OMET" Randomized Phase 2 Trial			
40644658	Reply to: Random Assignment, But Without Comparison: A Missed Opportunity	**Vernerey D**, Bachet JB, Sa Cunha A, Schwarz L.	J Clin Oncol	2025
40543509	UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity	Laheurte C, Boullerot L, Ndao B, Malfroy M, Queiroz L, Guillaume P, Loyon R, Seffar E, Gravelin E, Renaudin A, Jacquin M, Meurisse A, **Vernerey D**, Ghiringhelli F, Godet Y, Genolet R, Jandus C, Borg C, Adotévi O.	Cell Rep Med	2025
40415381	Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial)	Pretalli JB, **Vernerey D**, Evrard P, Pozet A, Clairet AL, Benoist S, Karoui M, Cotte E, Heyd B, Lakkis Z; FLUOCOL Study Group.	Colorectal Dis	2025
40389373	Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study	Depotte L, Nay P, Borg C, Meurisse A, Henriques J, Bennouna J, De La Fouchardière C, Tougeron D, Mazard T, Chibaudel B, Tournigand C, **Vernerey D**, Pigneur F, Andre T, Cohen R.	J Immunother Cancer	2025
40381378	Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases	Viot J, Loyon R, Adib N, Laurent-Puig P, de Reyniès A, André F, Monnien F, André T, Svrcek M, Turpin A, Selmani Z, Arnould L, Guyard L, Gilbert N, Boureux A, Adotevi O, Vienot A, Abdeljaoued S, **Vernerey D**, Borg C, Gautheret D.	EBioMedicine	2025
40184561	Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)	Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, Hammel P, Regenet N, Taieb J, Turrini O, Paye F, Turpin A, Souche FR, Laurent C, Kianmanesh R, Michel P, **Vernerey D**, Mabrut JY, Turco C, Truant S, Sa Cunha A.	J Clin Oncol	2025
40036378	Ipilimumab + nivolumab in combination vs. nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort	Nardin C, **Vernerey D**, Aubin F.	Br J Dermatol	2025
39938127	Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy	Cabrit N, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Wijnhoven B, **Vernerey D**, Smithers BM, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Gebski V, Burmeister B, Paoletti X, Sandick JV, Fu J, Pignon JP, Ducreux M, Faron M, Michiels S; MANATEC-02 collaborative group.	Eur J Cancer	2025
39903903	Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials	Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, Bennouna J, Artru P, Louvet C, Lepere C, Emile JF, Bouche O, Mazard T, **Vernerey D**, Vogiatzoglou K, Tzardi M, Sharma S, Liu MC, Sethi H, André T, Galon J, Laurent-Puig P.	J Clin Oncol	2025
39897613	First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort	Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, **Vernerey D**, Vincens M, Chanez B, Tougeron D, Tournigand C, Assenat E, Delaye M, Manfredi S, Bouché O, Williet N, Vienot A, Blaise L, Mas L, Neuzillet C, Boilève A, Roth GS.	JHEP Rep	2024
39889251	Prognostic Models From Transcriptomic Signatures of the	Gallois C, Sroussi M, André T, Mouillet-Richard S, Agueeff N, Mulot C,	J Clin Oncol	2025

	Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials	**Vernerey D**, Louvet C, Bachet JB, Dourthe LM, Mazard T, Jary M, Coutzac C, Lecaille C, Tabernero J, Van Laethem JL, Lepage C, Emile JF, de Reyniès A, Taieb J, Laurent-Puig P.		
39825571	Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity	Parent P, Pigneur F, Hilmi M, Carnot A, Garcia Larnicol ML, **Vernerey D**, Luciani A, Hammel P, Henriques J, Neuzillet C, Turpin A.	J Cachexia Sarcopenia Muscle	2025
39807836	Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials	Vienot A, **Vernerey D**, Bouard A, Klajer E, Kim S, Tournigand C, Louvet C, André T, Rousseau B, Wespiser M, Spehner L, Wang YA, Weispfenning A, Dochy E, Borg C.	Cancer Res Commun	2025
39612953	Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR	Thariat J, Bosset M, Falcoz A, **Vernerey D**, Pointreau Y, Racadot S, Faivre JC, Castelli J, Guihard S, Huguet F, Chapet S, Tao Y, Borel C, Fayette J, Rambeau A, Ferrand FR, Pechery A, Bourhis J, Sun XS; GORTEC, 4bis rue Emile Zola, Tours.	Int J Radiat Oncol Biol Phys	2025
39563716	SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors	Hammel P, Smith D, Afchain P, Dominguez-Tinajero S, Seitz JF, Lievre A, Van Cutsem E, Assenat E, Di Fiore F, Peeters M, Sobhani I, Raymond E, Charton E, **Vernerey D**, De Mestier L, Lombard-Bohas C.	Ther Adv Med Oncol	2024
39143002	Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial	Oudard S, Tran Y, Helissey C, Vauchier C, Ratta R, Bennamoun M, Voog E, Hasbini A, Thiery-Vuillemin A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, **Vernerey D**, Falcoz A, Youcef-Ali K, Kotti S, Lepicard EM, Barthelemy P.	Eur Urol Oncol	2025
39101207	New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial	Pinson J, Henriques J, Beaussire L, Sarafan-Vasseur N, Sa Cunha A, Bachet JB, **Vernerey D**, Di Fiore F, Schwarz L; PANACHE01-PRODIGE48 group.	Ann Surg	2024
39011625	A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial	Samaille T, Falcoz A, Cohen R, Laurent-Puig P, André T, Taieb J, Auclin E, **Vernerey D**.	Oncologist	2024
39010133	A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ study	Zaidi F, Calame P, Chevalier C, Henriques J, **Vernerey D**, Vuitton L, Heyd B, Borg C, Boustani J.	Radiat Oncol	2024
39004550	Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort	Delaye M, Boilève A, Henriques J, Rouault A, Paccard JR, Fares N, Assenat E, Lecomte T, Hautefeuille V, Tougeron D, Edeline J, Boileau C, Ducroux A, Hollebecque A, **Vernerey D**, Turpin A, Neuzillet C.	Dig Liver Dis	2025
38972830	Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer	El Kaddissi A, **Vernerey D**, Falcoz A, Mansi L, Bazan F, Chaigneau L, Dobi E, Goujon M, Meneveau N, Paillard MJ, Selmani Z, Viot J, Molimard C, Monnien F, Woronoff AS, Curtit E, Borg C, Meynard G.	Clin Breast Cancer	2024
38853098	Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study	Logeart J, Samaille T, Falcoz A, Svrcek M, Dubreuil O, **Vernerey D**, Cohen R, Cervera P, Valverde A, Parc Y, André T.	Clin Colorectal Cancer	2024
38824173	Interaction analysis of subgroup effects in randomized trials:	Fingerhut A, Uranues S, Dziri C, Ma J, **Vernerey D**, Kurihara H, Stiegler P.	Sci Rep	2024

	the essential methodological points			
38745088	Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases	Aparicio T, Henriques J, Svrcek M, Zaanan A, Manfredi S, Casadei-Gardini A, Tougeron D, Gornet JM, Jary M, Terrebonne E, Piessen G, Afchain P, Lecaille C, Pocard M, Lecomte T, Rimini M, Di Fiore F, Le Brun Ly V, Cascinu S, **Vernerey D**, Laurent Puig P.	Br J Cancer	2024
38588031	Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort	Lebeaud A, Antoun L, Paccard JR, Edeline J, Bourien H, Fares N, Tournigand C, Lecomte T, Tougeron D, Hautefeuille V, Viénot A, Henriques J, Williet N, Bachet JB, Smolenschi C, Hollebecque A, Macarulla T, Castet F, Malka D, Neuzillet C, **Vernerey D**, Boilève A, Turpin A.	Liver Int	2024
38547895	Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study	Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, **Vernerey D**, Taïeb J, Borg C.	Lancet Oncol	2024
38537314	A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability	Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, **Vernerey D**, Taieb J, Guimbaud R, Tougeron D.	Eur J Cancer	2024
39886486	Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial	Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, **Vernerey D**, Adotevi O, Borg C, Mansi L, Kroemer M.	BMJ Oncol	2023
37850342	Does Kono-S Anastomosis Reduce Recurrence in Crohn's Disease Compared with Conventional Ileocolonic Anastomosis? A Nationwide Propensity Score-matched Study from GETAID Chirurgie Group [KoCoRICCO Study]	Alibert L, Betton L, Falcoz A, Manceau G, Benoist S, Zerbib P, Podevin J, Maggiori L, Brouquet A, Tyrode G, Vuitton L, **Vernerey D**, Lefevre JH, Lakkis Z.	J Crohns Colitis	2024
37797388	Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer	Rasola C, Laurent-Puig P, André T, Falcoz A, Lepage C, Aparicio T, Bouché O, Lievre A, Mineur L, Bennouna J, Louvet C, Bachet JB, Borg C, **Vernerey D**, Lonardi S, Taieb J.	Eur J Cancer	2023
37776562	KONO-S Anastomosis Is Not Superior to Conventional Anastomosis for the Reduction of Postoperative Endoscopic Recurrence in Crohn's Disease	Tyrode G, Lakkis Z, **Vernerey D**, Falcoz A, Clairet V, Alibert L, Koch S, Vuitton L.	Inflamm Bowel Dis	2024
37774004	Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study	Zaanan A, Henriques J, Turpin A, Manfredi S, Coriat R, Terrebonne E, Legoux JL, Walter T, Locher C, Dubreuil O, Pernot S, Vernet C, Bouché O, Hautefeuille V, Gagniere J, Lecomte T, Tougeron D, Grainville T, **Vernerey D**, Afchain P, Aparicio T.	JNCI Cancer Spectr	2023
37707816	Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion	Gaiffe E, **Vernerey D**, Bardiaux L, Leroux F, Meurisse A, Bamoulid J, Courivaud C, Saas P, Hazzan M, Tiberghien P, Ducloux D.	JAMA Netw Open	2023
37516867	Evaluation of the interest to combine a CD4 Th1-inducer	Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat	BMC Cancer	2023

	cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)	E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, **Vernerey D**, Borg C.		
37480095	DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study	Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, **Vernerey D**, Meurisse A, Borg C.	Exp Hematol Oncol	2023
37467395	Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma	Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Shapiro J, **Vernerey D**, Smithers BM, Walsh T, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, de Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Roth J, Gebski V, Burmeister B, Paoletti X, van Sandick J, Fu J, Pignon JP, Ducreux M, Michiels S; MANATEC-02 Collaborative Group.	J Clin Oncol	2023
37390800	Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study	Bachet JB, Laurent-Puig P, Meurisse A, Bouché O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, **Vernerey D**, Taieb J.	Eur J Cancer	2023
37198562	A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study	Drozd C, Curtit E, Jacquinot Q, Marquine C, Mansi L, Chaigneau L, Dobi E, Viot J, Meynard G, Paillard MJ, Goujon M, Roux P, **Vernerey D**, Gillet V, Bourdin H, Galli S, Meneveau N, Mougin F.	BMC Cancer	2023
36535761	État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi	Delaye M, Assenat E, Boleslawski E, Camus M, Edeline J, Henriques J, Herrero A, Lièvre A, Malka D, Turpin A, **Vernerey D**, Neuzillet C.	Bull Cancer	2022
36211552	Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab	Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, **Vernerey D**, Pivot X, Mougin F.	Front Cardiovasc Med	2022
36207237	Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma	Le Roy C, **Vernerey D**, Evin C, Richard S, Crespel C, Samaille T, Le Tourneau C, Huguet F.	Clin Oncol (R Coll Radiol)	2022
36128685	StomaCare: quality of life impact after enhanced follow-up of ostomy patients by a home healthcare nursing service-a multicentre, randomized, controlled trial	de Ponthaud C, Roupret M, **Vernerey D**, Audenet F, Brouquet A, Cotte E, Cuvillier X, Kanso F, Meurette G, Ledaguenel P, Maggiori L, Neuzillet Y, Ouaissi M, Roumiguié M, Phé V, Vuong NS, Parc Y, Lefèvre JH.	Colorectal Dis	2023
36119522	Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma	Kim S, Boustani J, **Vernerey D**, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C.	Front Oncol	2022
36070539	Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa	Adotévi O, **Vernerey D**, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL,	J Clin Oncol	2023

	De-Escalation Study	Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V.		
36011035	Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?	De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, **Vernerey D**.	Cancers (Basel)	2022
35988887	Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review	Neuzillet C, Malka D, Lièvre A, Khurana IS, **Vernerey D**.	Clin Res Hepatol Gastroenterol	2022
35969830	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study	André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, **Vernerey D**, Henriques J, Lefevre JH, Svrcek M.	J Clin Oncol	2023
35928870	A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T(H)1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study	Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, **Vernerey D**, Meurisse A, Kim S, Borg C, Mansi L.	Front Oncol	2022
35711440	Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study	Gaiffe E, **Vernerey D**, Bardiaux L, Leroux F, Meurisse A, Bamoulid J, Courivaud C, Saas P, Tiberghien P, Ducloux D.	Front Immunol	2022
35546670	Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer	Eberst G, **Vernerey D**, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V.	BMC Cancer	2022
35489233	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study	Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, **Vernerey D**, Andre T, Hulin A.	Eur J Cancer	2022
35340264	Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients	Orillard E, Henriques J, **Vernerey D**, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S.	Front Oncol	2022
35337742	Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"	Coutzac C, Trouilloud I, Artru P, Henriques J, Masson T, Doat S, Bouché O, Coriat R, Saint A, Moulin V, **Vernerey D**, Gallois C, De La Fouchardière C, Tougeron D, Taieb J.	Clin Colorectal Cancer	2022
35306156	Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)	Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, **Vernerey D**, Taieb J, Svrcek M; for PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER.	Ann Oncol	2022
35262794	Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia	Eberst G, Claudé F, Laurent L, Meurisse A, Roux-Claudé P, Barnig C, **Vernerey D**, Paget-Bailly S, Bouiller K, Chirouze C, Behr J, Grillet F, Ritter O, Karaer S, Pili-Floury S, Winiszewski H, Samain E, Decavel P, Capellier G,	Ann Intensive Care	2022

		Westeel V.		
35038368	Is it safe to perform an anastomosis for rectal cancer after prostate cancer? A multicentre study of 126 patients from the GRECCAR group	Lakkis Z, Doussot A, Manfredelli S, **Vernerey D**, Meillat H, Ouaissi M, Cotte E, Faucheron JL, Piessen G, Tuech JJ, Lefevre JH, Panis Y, Beyer L, Brouquet A, Dumont F, Meurisse A, Rullier E, Heyd B; French Research Group of Rectal Cancer Surgery (GRECCAR).	Colorectal Dis	2022
34995900	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies	Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, **Vernerey D**, Borg C, Kim S.	Eur J Cancer	2022
34954864	Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study	Jary M, Liu WW, Yan D, Bai I, Muranyi A, Colle E, Brocheriou I, Turpin A, Radosevic-Robin N, Bourgoin P, Penault-Llorca F, Cohen R, **Vernerey D**, André T, Borg C, Shanmugam K, Svrcek M.	Mol Oncol	2022
34771628	Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey	Kasi A, Dotan E, Poage GM, Catteau A, **Vernerey D**, George M, Barzi A.	Cancers (Basel)	2021
34752136	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin	Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, **Vernerey D**, Oki E, Georgoulias V, Ben-Aharon I, Shi Q.	J Clin Oncol	2021
34439304	HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study	Baumann A, Henriques J, Selmani Z, Meurisse A, Lepiller Q, **Vernerey D**, Valmary-Degano S, Paget-Bailly S, Riethmuller D, Ramanah R, Mougin C, Prétet JL.	Cancers (Basel)	2021
34384712	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort	Allart M, Leroy F, Kim S, Sefrioui D, Nayeri M, Zaanan A, Rousseau B, Ben Abdelghani M, de la Fouchardière C, Cacheux W, Legros R, Louafi S, Tougeron D, Bouché O, Fares N, Roquin G, Bignon AL, Maillet M, Pozet A, Hautefeuille V; AGEO investigators.	Dig Liver Dis	2022
34123853	Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma	d'Engremont C, Grillot J, Raillat J, **Vernerey D**, Vuitton L, Koch S, Turco C, Heyd B, Mouillet G, Jacquinot Q, Borg C, Vienot A.	Front Oncol	2021
34083233	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial	Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, **Vernerey D**, André T, Laurent-Puig P.	Clin Cancer Res	2021
33934494	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment	Pastor B, André T, Henriques J, Trouilloud I, Tournigand C, Jary M, Mazard T, Louvet C, Azan S, Bauer A, Roch B, Sanchez C, **Vernerey D**, Thierry AR, Adenis A.	Mol Oncol	2021
33898048	Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients	Garnier L, Charton E, Falcoz A, Paget-Bailly S, **Vernerey D**, Jary M, Ducray F, Curtit E.	Neurooncol Pract	2020
33561507	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma	Giraud P, Racadot S, **Vernerey D**, Goldstein D, Glimelius B, Van Houtte P, Gubanski M, Spry N, Van Laethem JL, Hammel P, Huguet F.	Int J Radiat Oncol Biol Phys	2021

33548338	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma	Schernberg A, **Vernerey D**, Goldstein D, Van Laethem JL, Glimelius B, van Houtte P, Bonnetain F, Louvet C, Hammel P, Huguet F.	Int J Radiat Oncol Biol Phys	2021
33329760	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma	Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, **Vernerey D**, Borg C.	Ther Adv Med Oncol	2020
33279854	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial	Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanié H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, **Vernerey D**, Turpin A, Neuzillet C.	Eur J Cancer	2021
33271092	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials	André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, **Vernerey D**, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q.	Lancet Oncol	2020
33186471	Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort	Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, **Vernerey D**, Puig PL.	Int J Cancer	2021
33148693	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study	Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, **Vernerey D**, Menu Y, André T.	J Immunother Cancer	2020
33055007	Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma	McLellan P, Henriques J, Ksontini F, Doat S, Hammel P, Desrame J, Trouilloud I, Louvet C, Pietrasz D, **Vernerey D**, Bachet JB.	Clin Res Hepatol Gastroenterol	2021
33026940	How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial	Kim S, **Vernerey D**, Borg C.	J Clin Oncol	2020
32957741	Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials	Spehner L, Kim S, Vienot A, François E, Buecher B, Adotevi O, **Vernerey D**, Abdeljaoued S, Meurisse A, Borg C.	Int J Mol Sci	2020
32886823	FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study	Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, **Vernerey D**, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A.	Oncologist	2020
32789966	Exposure-response analysis of Raltitrexed assessing liver toxicity	Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, **Vernerey D**, Henriques J, Jacquin M, Borg C, Kim S.	Br J Clin Pharmacol	2021
32653357	Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR	Pagès F, André T, Taieb J, **Vernerey D**, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, Bennouna J, Desrame J, Faroux R, Kirilovsky A, Duval A, Laurent-Puig P, Svrcek M, Hermitte F, Catteau A, Galon J, Emile	Ann Oncol	2020

	cohort study': Annals of Oncology 2020; Volume 31: 921-929	JF.		
32620211	Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE	Gassian N, Frontczak A, Mouillet G, **Vernerey D**, Manseur O, Goujon M, Meurisse A, Berthod D, Robert E, Calcagno F, Thiery-Vuillemin A.	Bull Cancer	2020
32525595	Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer	Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, **Vernerey D**; AGEO (Association des Gastro-Entérologues Oncologues) Investigators; GICO (Italian Group of Cholangiocarcinoma) Investigators.	Int J Cancer	2020
32500342	Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group	Doussot A, **Vernerey D**, Rullier E, Lefevre JH, Meillat H, Cotte E, Piessen G, Tuech JJ, Panis Y, Mege D, Meurisse A, De Bari B, Heyd B, Lakkis Z; French Research Group of Rectal Cancer Surgery (GRECCAR).	Ann Surg Oncol	2020
32471382	NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)	Brouquet A, Bachet JB, Huguet F, Karoui M, Artru P, Sabbagh C, Lefèvre JH, **Vernerey D**, Mariette C, Vicaut E, Benoist S; on behalf the FRENCH , GRECCAR, PRODIGE study groups.	BMC Cancer	2020
32415973	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin	Zaanan A, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, Lecomte T, Aparicio T, Svrcek M, Taieb J, André T, **Vernerey D**, Tougeron D; Association des Gastro-entérologues Oncologues (AGEO).	J Natl Cancer Inst	2021
32334548	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial	Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, **Vernerey D**, Borg C.	BMC Cancer	2020
32294529	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study	Pagès F, André T, Taieb J, **Vernerey D**, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, Bennouna J, Desrame J, Faroux R, Kirilovsky A, Duval A, Laurent-Puig P, Svrcek M, Hermitte F, Catteau A, Galon J, Emile JF.	Ann Oncol	2020
32206183	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study	Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, **Vernerey D**.	World J Gastrointest Oncol	2020
32172199	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative	Cohen R, **Vernerey D**, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group.	Eur J Cancer	2020
32167864	Prognostic Value of Tumor Deposits for Disease-Free Survival	Delattre JF, Cohen R, Henriques J, Falcoz A, Emile JF, Fratte S, Chibaudel B,	J Clin Oncol	2020

	in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)	Dauba J, Dupuis O, Bécouarn Y, Bibeau F, Taieb J, Louvet C, **Vernerey D**, André T, Svrcek M.		
32126964	Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)	Schwarz L, **Vernerey D**, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS.	BMC Cancer	2020
32057467	[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]	Cohen R, Pudlarz T, Garcia-Larnicol ML, **Vernerey D**, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T.	Bull Cancer	2020
31970760	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study	Tougeron D, Sueur B, Zaanan A, de la Fouchardiére C, Sefrioui D, Lecomte T, Aparicio T, Des Guetz G, Artru P, Hautefeuille V, Coriat R, Moulin V, Locher C, Touchefeu Y, Lecaille C, Goujon G, Ferru A, Evrard C, Chautard R, Gentilhomme L, **Vernerey D**, Taieb J, André T, Henriques J, Cohen R; Association des Gastro-entérologues Oncologues (AGEO).	Int J Cancer	2020
31959341	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group	André T, **Vernerey D**, Im SA, Bodoky G, Buzzoni R, Reingold S, Rivera F, McKendrick J, Scheithauer W, Ravit G, Fountzilas G, Yong WP, Isaacs R, Österlund P, Liang JT, Creemers GJ, Rakez M, Van Cutsem E, Cunningham D, Tabernero J, de Gramont A.	Ann Oncol	2020
31912484	Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients	Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, **Vernerey D**, Afchain P; NADEGE Investigators.	Int J Cancer	2020
31648924	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study	Auvray M, Tougeron D, Auclin E, Moulin V, Artru P, Hautefeuille V, Hammel P, Lecomte T, Locher C, Sickersen G, Coriat R, Lecaille C, **Vernerey D**, Taieb J, Pernot S.	Clin Colorectal Cancer	2020
31641948	Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial	Makhloufi S, Turpin A, El Amrani M, André T, Truant S, Bachet JB, **Vernerey D**, Hebbar M.	Ann Surg Oncol	2020
31564556	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan	Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, **Vernerey D**, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F.	Clin Colorectal Cancer	2019
31404579	Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer	Meillan N, **Vernerey D**, Lefèvre JH, Manceau G, Svrcek M, Augustin J, Fléjou JF, Lascols O, Simon JM, Cohen R, Maingon P, Bachet JB, Huguet F.	Int J Radiat Oncol Biol Phys	2019
31358938	Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer	Laheurte C, Dosset M, **Vernerey D**, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O.	Br J Cancer	2019
31319569	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended	Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R,	Cancers (Basel)	2019

	Mutation Analysis from the AGEO RASANC Study	Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, **Vernerey D**, Laurent-Puig P.		
31296923	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial	Auclin E, André T, Taieb J, Banzi M, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, **Vernerey D**.	Br J Cancer	2019
31263053	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials	Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, **Vernerey D**.	Cancer Epidemiol Biomarkers Prev	2019
31227028	PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study	Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Büchler M, Cassuto E, Albano L, Chemouny JM, Choukroun G, Hazzan M, Kessler L, Legendre C, Le Meur Y, Ouali N, Thierry A, Anota A, Nerich V, Limat S, Bonnetain F, **Vernerey D**, Ducloux D.	Trials	2019
31209667	Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial	Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, **Vernerey D**, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J.	Ann Surg Oncol	2019
31074509	Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy	Lakkis Z, **Vernerey D**, Mege D, Faucheron JL, Panis Y, Tuech JJ, Lefevre JH, Brouquet A, Dumont F, Borg C, Woronoff AS, Meurisse A, Heyd B, Rullier E; French Research Group of Rectal Cancer Surgery (GRECCAR).	Br J Surg	2019
31019704	Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score	de Mestier L, Muller M, Cros J, Vullierme MP, **Vernerey D**, Maire F, Dokmak S, Rebours V, Sauvanet A, Lévy P, Hammel P.	United European Gastroenterol J	2019
30987751	[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research]	Hilmi M, Rousseau B, Cohen R, Vienot A, **Vernerey D**, Bartholin L, Blanc-Durand F, Louvet C, Turpin A, Neuzillet C.	Bull Cancer	2019
30826661	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations	Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, **Vernerey D**; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort.	Eur J Cancer	2019
30717745	Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol	Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, **Vernerey D**, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A.	Health Qual Life Outcomes	2019
30358867	Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)	Benomar M, Vachey C, Lobbedez T, Henriques J, Ducloux D, **Vernerey D**, Courivaud C.	Nephrol Dial Transplant	2019
30042063	Docetaxel, cisplatin, and fluorouracil chemotherapy for	Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N,	Lancet Oncol	2018

	metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study	Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, **Vernerey D**, Taieb J, Vendrely V, Buecher B, Borg C.		
30041614	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)	Schwarz L, **Vernerey D**, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS.	BMC Cancer	2018
29731226	Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments	Auclin E, André T, Taieb J, Benetkiewicz M, de Gramont A, **Vernerey D**.	Eur J Cancer	2018
29650037	Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial	Mouillet G, Paillard MJ, Maurina T, **Vernerey D**, Nguyen Tan Hon T, Almotlak H, Stein U, Calcagno F, Berthod D, Robert E, Meurisse A, Thiery-Vuillemin A.	Trials	2018
29620995	Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial	André T, **Vernerey D**, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.	J Clin Oncol	2018
29590544	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer	Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, **Vernerey D**, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.	N Engl J Med	2018
29484276	Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies	Magne J, Jenvrin A, Chauchet A, Casasnovas O, Donzel A, Jego L, Aral B, Guy J, Nadal N, **Vernerey D**, Callier P, Garnache-Ottou F, Ferrand C.	Exp Hematol Oncol	2018
29438522	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study	Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, **Vernerey D**, Laurent-Puig P.	Ann Oncol	2018
29055842	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency	Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, **Vernerey D**, Duval A, Svrcek M, André T.	Eur J Cancer	2017
28629338	A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study	Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, **Vernerey D**, Pivot X, Mougin F.	BMC Cancer	2017

28453690	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy	Auclin E, Zaanan A, **Vernerey D**, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.	Ann Oncol	2017
28383673	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma	Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, **Vernerey D**.	J Natl Cancer Inst	2017
27938329	Erratum to: Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty	**Vernerey D**, Anota A, Vandel P, Paget-Bailly S, Dion M, Bailly V, Bonin M, Pozet A, Foubert A, Benetkiewicz M, Manckoundia P, Bonnetain F.	BMC Geriatr	2016
27855641	Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty	**Vernerey D**, Anota A, Vandel P, Paget-Bailly S, Dion M, Bailly V, Bonin M, Pozet A, Foubert A, Benetkiewicz M, Manckoundia P, Bonnetain F.	BMC Geriatr	2016
27782813	Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study	d'Engremont C, **Vernerey D**, Pointet AL, Simone G, Fein F, Heyd B, Koch S, Vuitton L, Kim S, Jary M, Lamfichek N, Turco C, Lakkis Z, Berger A, Bonnetain F, Taieb J, Bachellier P, Borg C.	BMC Cancer	2016
27493255	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss	Viglietti D, Loupy A, **Vernerey D**, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C.	J Am Soc Nephrol	2017
27472156	Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score	Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, **Vernerey D**.	Int J Cancer	2016
27404456	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)	**Vernerey D**, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F.	Br J Cancer	2016
27353036	MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors	Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, **Vernerey D**, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.	Endocr Relat Cancer	2016
27252150	Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma	Paquette B, **Vernerey D**, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.	Cancer Med	2016
26839356	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study	Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, **Vernerey D**, Bonnetain F, Michel P, Taïeb J, Zaanan A.	J Natl Cancer Inst	2016
26682871	Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients	Fiteni F, **Vernerey D**, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.	Eur J Cancer	2016
26527776	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study	André T, de Gramont A, **Vernerey D**, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.	J Clin Oncol	2015

26474518	Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial	Tournigand C, Chibaudel B, Samson B, Scheithauer W, **Vernerey D**, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A.	Lancet Oncol	2015
26293822	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury	Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, **Vernerey D**, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A.	J Am Soc Nephrol	2016
26260807	Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial	Guiu S, Charon-Barra C, **Vernerey D**, Fumoleau P, Campone M, Spielmann M, Roché H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M.	Future Oncol	2015
26232393	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study	Aubert O, Kamar N, **Vernerey D**, Viglietti D, Martinez F, Duong-Van-Huyen JP, Eladari D, Empana JP, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A.	BMJ	2015
29371517	Investigation of the Matrix Metalloproteinase-2 Gene in Patients with Non-Syndromic Mitral Valve Prolapse	Perrocheau M, Kiando SR, **Vernerey D**, Dina C, Galan P, Hagege A, Jeunemaitre X, Bouatia-Naji N.	J Cardiovasc Dev Dis	2015
26056252	Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies	Loupy A, **Vernerey D**, Viglietti D, Aubert O, Duong Van Huyen JP, Empana JP, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C.	Circ Res	2015
26027598	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology	Fiteni F, Pam A, Anota A, **Vernerey D**, Paget-Bailly S, Westeel V, Bonnetain F.	Expert Rev Anticancer Ther	2015
25864037	Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study	Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, **Vernerey D**, Bonnetain F, Michel P, Taïeb J, Lecomte T; Association des Gastro-Entérologues Oncologues (AGEO).	Eur J Cancer	2015
25644326	Early detection of asymptomatic bypass graft abnormalities using a cardiac troponin I ratio following coronary artery bypass surgery	Perrotti A, Luporsi P, Durst C, **Vernerey D**, Chocron S.	J Card Surg	2015
25612500	Inflammatory cell burden and phenotype in endomyocardial biopsies with antibody-mediated rejection (AMR): a multicenter pilot study from the AECVP	Fedrigo M, Leone O, Burke MM, Rice A, Toquet C, **Vernerey D**, Frigo AC, Guillemain R, Pattier S, Smith J, Lota A, Potena L, Bontadini A, Ceccarelli C, Poli F, Feltrin G, Gerosa G, Manzan E, Thiene G, Bruneval P, Angelini A, Duong Van Huyen JP.	Am J Transplant	2015
25595830	Neutrophil gelatinase-associated lipocalin as early predictor of acute kidney injury after cardiac surgery in adults with chronic kidney failure	Perrotti A, Miltgen G, Chevet-Noel A, Durst C, **Vernerey D**, Bardonnet K, Davani S, Chocron S.	Ann Thorac Surg	2015
25583947	Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma	Jary M, **Vernerey D**, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouché O, Fratte S, Gonçalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C.	Cancer Epidemiol Biomarkers Prev	2015
25556173	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts	Loupy A, **Vernerey D**, Tinel C, Aubert O, Duong van Huyen JP, Rabant M, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C.	J Am Soc Nephrol	2015

25222117	Kidney allograft fibrosis after transplantation from uncontrolled circulatory death donors	Viglietti D, Abboud I, Hill G, **Vernerey D**, Nochy D, Antoine C, Fieux F, Assayag M, Verine J, Gaudez F, Loupy A, Glotz D, Lefaucheur C.	Transplantation	2015
25176944	MicroRNAs as non-invasive biomarkers of heart transplant rejection	Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, Iserin F, Rouvier P, François A, **Vernerey D**, Loyer X, Leprince P, Empana JP, Bruneval P, Loupy A, Jouven X.	Eur Heart J	2014
25111859	Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review	Fiteni F, Nguyen T, **Vernerey D**, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X.	Cancer Med	2014
24700874	Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection	Loupy A, Lefaucheur C, **Vernerey D**, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF.	J Am Soc Nephrol	2014
24440056	Endpoints in cancer clinical trials	Fiteni F, Westeel V, Pivot X, Borg C, **Vernerey D**, Bonnetain F.	J Visc Surg	2014
24066742	Complement-binding anti-HLA antibodies and kidney-allograft survival	Loupy A, Lefaucheur C, **Vernerey D**, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X.	N Engl J Med	2013
23856214	Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation	Tible M, Loupy A, **Vernerey D**, Suberbielle C, Beuscart T, Cazes A, Guillemain R, Amrein C, Pezzella V, Fabiani JN, Nochy D, Hill G, Empana JP, Jouven X, Charron D, Bruneval P, Duong Van Huyen JP.	J Heart Lung Transplant	2013
23182298	Antibody-mediated vascular rejection of kidney allografts: a population-based study	Lefaucheur C, Loupy A, **Vernerey D**, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X.	Lancet	2013
22337682	Main air pollutants and myocardial infarction: a systematic review and meta-analysis	Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, Périer MC, Marijon E, **Vernerey D**, Empana JP, Jouven X.	JAMA	2012
21672156	Delineating the picture of renal graft injury in 2011	Loupy A, **Vernerey D**, Hill GS, Legendre Ch, Anglicheau D.	Am J Transplant	2011
21199348	Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)	Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, Timsit MO, Duong JP, Bruneval P, **Vernerey D**, Empana JP, Jouven X, Nochy D, Legendre CH.	Am J Transplant	2011
20972245	A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency	Lebre AS, Rio M, Faivre d'Arcier L, **Vernerey D**, Landrieu P, Slama A, Jardel C, Laforêt P, Rodriguez D, Dorison N, Galanaud D, Chabrol B, Paquis-Flucklinger V, Grévent D, Edvardson S, Steffann J, Funalot B, Villeneuve N, Valayannopoulos V, de Lonlay P, Desguerre I, Brunelle F, Bonnefont JP, Rötig A, Munnich A, Boddaert N.	J Med Genet	2011
19888426	Analysis of candidate genes in occurrence and growth of colorectal adenomas	Olschwang S, **Vernerey D**, Cottet V, Pariente A, Nalet B, Lafon J, Faivre J, Laurent-Puig P, Bonithon-Kopp C, Bonaiti-Pellié C.	J Oncol	2009
18692814	Absence of association between a functional polymorphism of ALOX15 gene and infertility in endometriosis	Borghese B, Gayet V, Chiche JD, **Vernerey D**, de Ziegler D, Bonaiti-Pellié C, Chapron C.	Fertil Steril	2009
18308831	Genetic polymorphisms of matrix metalloproteinase 12 and 13 genes are implicated in endometriosis progression	Borghese B, Chiche JD, **Vernerey D**, Chenot C, Mir O, Bijaoui G, Bonaiti-Pellié C, Chapron C.	Hum Reprod	2008
16871232	Variability of naked DNA expression after direct local injection: the influence of the injection speed	André FM, Cournil-Henrionnet C, **Vernerey D**, Opolon P, Mir LM.	Gene Ther	2006

16435508	Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma	Elias D, Benizri E, **Vernerey D**, Eldweny H, Dipietrantonio D, Pocard M.	Gastroenterol Clin Biol	2005
16228842	Quality of life of patients operated on for low rectal cancer: impact of the type of surgery and patients' characteristics	Sideris L, Zenasni F, **Vernerey D**, Dauchy S, Lasser P, Pignon JP, Elias D, Di Palma M, Pocard M.	Dis Colon Rectum	2005
16184442	Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect	Elias D, Liberale G, **Vernerey D**, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P.	Ann Surg Oncol	2005

06/11/2026

